RxDoctor Payments Data

Zachary Gula, PA

Physician Assistant · Toledo, OHNPI 1720507320

Payments from drug & device makers

$2,352in general payments, 2019–2025

Across 120 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$600
  • Supernus Pharmaceuticals, Inc.$348
  • Otsuka America Pharmaceutical, Inc.$239
  • AbbVie$171
  • Sunovion Pharmaceuticals Inc.$162
  • Vanda Pharmaceuticals Inc.$147
  • plus $685 from 14 others

What the payments were for

  • Food & beverage$2,30698%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,352 in reported general payments places this provider in the 85th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$10,747
Medicare patients
33
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate11$16,879
Lurasidone Hcl22$9,990
Quetiapine Fumarate ErQuetiapine Fumarate14$4,002
Fluoxetine Hcl77$2,182
Aripiprazole24$1,864
Buspirone Hcl52$1,770
Risperidone82$1,689
Quetiapine Fumarate73$1,190
Atomoxetine Hcl12$1,165
Olanzapine47$1,080
Vilazodone Hcl12$1,077
Guanfacine Hcl ErGuanfacine Hcl19$934
Methylphenidate ErMethylphenidate Hcl11$827
Trazodone Hcl72$827
Divalproex Sodium ErDivalproex Sodium15$745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$600$16,87911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →